Autoimmune & Rheumatology Clinical Trials Update: Week 40, 2026

Published October 2, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis

This study explores different ways to safely reduce or stop biologic TNFi treatment in children with juvenile spondyloarthritis who have inactive disease. By involving 164 children from 31 pediatric centers across the US and Canada, the trial aims to find easier and safer treatment plans that may lower medication use while minimizing the risk of disease flare-ups. This could lead to more manageable care for young patients and their families.

ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months.

This Phase 3 trial is testing treatments such as hydroxychloroquine and corticosteroids for children suffering from acute rheumatic fever and heart inflammation. Recruiting 600 participants in New Zealand, the study hopes to discover better ways to reduce heart damage and improve health outcomes in affected children. The findings may offer new hope for families dealing with this serious condition.

Pediatric Arthritis Study of Certolizumab Pegol

Completed across multiple countries, this Phase 3 trial evaluated the drug certolizumab pegol in children and adolescents with moderately to severely active polyarticular juvenile idiopathic arthritis. The study results, now available, could provide a new treatment option that helps ease symptoms and improve quality of life for young people living with this form of autoimmune arthritis.

Group-Based Psychological Treatments Over Video Conference for Older Veterans With Chronic Pain

This study is testing three types of group-based psychological therapies delivered by video conference for older veterans experiencing chronic musculoskeletal pain. With 216 participants planned in the United States, these treatments may offer safer and more accessible alternatives to medications or procedures, potentially helping veterans better manage their pain from home.

A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

This Phase 3 trial is investigating ecnoglutide injections in obese adults with knee osteoarthritis in China, enrolling 360 participants. The goal is to see if this treatment can safely reduce joint pain and improve mobility by addressing both weight and osteoarthritis symptoms. Success here could mean a new option for people struggling with these overlapping health challenges.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.